Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus thalidomide maintenance after chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2600120817Phase 4Completed
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and thalidomide in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: One-year progression-free survival rate and Safety. Started Mar 2026; status: completed.
02
Drugs
camrelizumabthalidomide
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600120817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120817.